Zelicapavir (Enanta Pharmaceuticals), an oral once-daily inhibitor of the respiratory syncytial virus (RSV) N-protein, shortened time to complete and sustained resolution of RSV symptoms by up to 1 week in high-risk adults.1 The antiviral did not, however, improve time to resolution of symptoms to mild or absent, the trial's primary end point. Christopher E. Harris, MD, senior medical director at Enanta, presented the phase 2 data at IDWeek 2026, held October 21-24 in Washington, DC.1
Adults with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or asthma, and those older than 65 years, face elevated risk of severe RSV disease.1 No RSV antiviral had previously shown efficacy in this population, according to the investigators. The trial enrolled outpatients, and zelicapavir was given orally for 5 days.1,2
"This represents the first time an RSV antiviral treatment has demonstrated a clinically meaningful benefit in these high-risk adult outpatients," Scott T. Rottinghaus, MD, chief medical officer of Enanta Pharmaceuticals, said in a statement issued in September, upon the announcement of the topline data.2
In speaking with Contagion about the trial and its design, Rottinghaus said, “Nobody had actually shown a meaningful clinical benefit in this population with an antiviral before, so there wasn’t preexisting data to guide either what the primary end point should be or how exactly to measure it,” adding that the resolution of symptoms is a potentially more straightforward measure for patients. “Having a patient judge whether his symptoms are moderate or mild is somewhat subjective. Whereas if you ask a patient, ‘Do you have symptoms or not?’ that’s fairly objective… So I think patients can report complete resolution of symptoms in a more repeatable way,” he said.
Zelicapavir Phase 2 Trial Design and Primary End Point Results
In the global, randomized, double-blind, placebo-controlled trial, 186 symptomatic adults with CHF, COPD, or asthma, or older than 65 years, received zelicapavir (n = 121) or placebo (n = 65) once daily for 5 days. Participants enrolled within 3 days of symptom onset. A predefined higher-risk population with CHF, COPD, or age older than 75 years (HR3) made up 81% of the efficacy population.1